What is Recormon? Recormon contains the main active ingredient Epoetin Beta and other excipients in sufficient quantities. Recormon is indicated for use in the treatment of anemia. Refer to the article below for more useful information about this drug.
1. What are the effects of Recormon?
The active ingredient Erythropoietin in Recormon is a glycoprotein, a growth factor whose main effect is to stimulate the formation of red blood cells from precursor cells. This substance acts as a factor that stimulates cell division and differentiation hormones.
Recormon is indicated for use in the following cases:
- Treatment of symptomatic anemia caused by chronic renal failure in patients undergoing renal replacement therapy.
- Treatment of symptomatic anemia due to kidney disease in patients not yet requiring dialysis.
- Disease prevention anemia for premature babies with birth weight from 750g to 1500g and gestational age less than 34 weeks.
- Treatment of symptomatic anemia in adults with malignant tumor not in the pulp being treated with chemotherapy.
- Increase autologous blood production for people in the blood donation preparation period.
The use of the drug in this indication should be considered in light of the reported increased risk of thromboembolism. Treatment should only be used in people with moderate anemia with Hb 10 - 13 g/dl (6.21-8.07 mmol/l) and no iron deficiency.
Recormon is contraindicated in the following cases:
- People with a history of sensitivity or hypersensitivity to the main active ingredient or any ingredient of the drug.
- People with poorly controlled high blood pressure.
- In the indication “increasing the amount of autologous blood”, Recormon should not be used for patients who have had a heart attack or stroke in the previous month of treatment, or for people with unstable angina. Recormon should also not be used for people who are at risk of deep vein thrombosis, specifically those with a history of venous thromboembolism.
2. How to use and dosage of Recormon
2.1. How to use Recormon
- Recormon medicine is used as a subcutaneous or intravenous.
- Substitution by any other biological medicine requires the consent of the prescribing physician.
- Epoetin beta prefilled syringes are ready for use.
- Never reuse the syringe under any circumstances, the medicine is for single injection only.
2.2. Therapeutic dose of the drug
- For adults on chronic hemodialysis: 50 IU/kg/dose x 3 times/week intravenously, 40 IU/kg/dose x 3 times/week subcutaneously.
- For people who do not need dialysis: Inject 75 - 100 IU/kg per week.
- For people infected with HIV being treated with Zidovudine: 100 IU/kg x 3 times/week intravenously or subcutaneously, maximum dose 300 IU/kg x 3 times/week.
- For cancer patients undergoing chemotherapy: 150 IU/kg x 3 times/week subcutaneous injection.
- Blood transfusion for surgical patients: 300 IU/kg/day subcutaneously for 10 days before surgery.
- Treatment of anemia in premature infants: 250 IU/kg x 3 times/week subcutaneously from the 2nd week after birth and used for the next 8 weeks.
Note: The above dosages are for reference only. Specific dosages depend on individual health conditions and the severity of the disease. Consult a healthcare provider for appropriate dosing.
In case of overdose: The therapeutic dose range of Recormon is very wide and individual response to treatment should be considered when starting Recormon. Overdose of Recormon may cause manifestations that exaggerate the pharmacodynamic effects, in particular excessive erythropoiesis which may lead to cardiovascular complications that may be life-threatening. If the hemoglobin concentration increases too much, Recormon should be temporarily discontinued. If treatment is indicated, phlebotomy may be performed.
If you miss a dose, you should take it as soon as possible. However, if it is close to the time for your next dose, skip the missed dose and take your next dose at the scheduled time. Do not take a double dose.
3. Undesirable effects of Recormon
The most common adverse effects, especially in the early stages of treatment with Recormon, are signs of hypertension including increased blood pressure, and hypertensive crises with symptoms similar to encephalopathy. Specifically, headaches and confusion, sensory-motor disturbances such as dysarthria or unsteady gait, up to tonic-clonic seizures may occur. This phenomenon can occur in people with normal blood pressure or as a worsening manifestation of pre-existing hypertension.
- Common side effects include: vascular disorder high blood pressure, and nervous system disorders such as headaches.
- Rare adverse effects include vascular disorders, specifically hypertensive crisis.
- Rare adverse effects include blood and lymphatic system disorders, specifically thrombosis.
- Very rare side effects are blood and lymphaic system disorders: Thrombocytosis.
When experiencing side effects of the drug, you need to proactively stop using it and notify your doctor or go to the nearest medical facility for timely treatment.
4. Drug interactions of Recormon
No specific studies on the interaction of Recormon with other drugs have been performed. The clinical results obtained to date do not indicate any interaction between Recormon and other active substances.
Concomitant use of Recormon with ACE inhibitors may increase the risk of hyperkalemia, especially in patients with renal failure. In animal studies, Recormon did not increase the bone marrow toxicity of cytotoxic drugs such as etoposide, cyclophosphamide, cisplatin, and fluorouracil.
5. Precautions
- No studies on the effects of Recormon on the ability to drive and use machines have been performed. However, no effects are expected based on the mechanism of action and the known safety profile of Recormon.
- Animal studies have not shown any direct or indirect toxic effects on pregnancy, embryonal and fetal development, parturition, or postnatal development. However, due to the lack of clinical data, caution should be exercised when prescribing Recormon to pregnant women.
- Experience with the use of Recormon in breast-feeding women is limited. Endogenous erythropoietin is excreted in breast milk and is rapidly absorbed from the gastrointestinal tract of the newborn. A decision on whether to continue or discontinue breast-feeding or to continue or discontinue therapy with Recormon should be made by the physician taking into account the benefit of breast-feeding to the child and the benefit of Recormon to the woman.
- For children: In the indication for the treatment of anemia caused by chronic kidney disease, Recormon is not used for young children (or children under 2 years old). In the indication for the treatment of anemia in cancer treatment using chemotherapy and treatment to mobilize autologous blood sources, Recormon is not indicated for children.
To arrange an appointment, please call HOTLINE or make your reservation directly HERE. You may also download the MyVinmec app to schedule appointments faster and manage your reservations more conveniently.
